AR085086A1 - Uso de analogos de glucagon acilados - Google Patents
Uso de analogos de glucagon aciladosInfo
- Publication number
- AR085086A1 AR085086A1 ARP120100195A ARP120100195A AR085086A1 AR 085086 A1 AR085086 A1 AR 085086A1 AR P120100195 A ARP120100195 A AR P120100195A AR P120100195 A ARP120100195 A AR P120100195A AR 085086 A1 AR085086 A1 AR 085086A1
- Authority
- AR
- Argentina
- Prior art keywords
- arg
- leu
- ala
- ser
- asp
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Child & Adolescent Psychology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Procedimientos para tratar trastornos metabólicos, incluyendo diabetes, mediante el uso de una combinación de un análogo de glucagón acilado y un análogo de insulina. Kit que incluye un análogo de glucagón acilado y un análogo de insulina.Reivindicación 1: Una combinación de compuestos para uso en un procedimiento para prevenir o reducir el aumento de peso; promover la pérdida de peso; mejorar los niveles de glucosa circulante, la tolerancia a la glucosa o los niveles de colesterol circulante; reducir los niveles de LDL circulante; aumentar la relación HDL/LDL; o tratar una afección producida o caracterizada por un exceso de peso corporal, en la que dicho procedimiento comprende administrar a un sujeto mamífero una combinación de compuestos, que comprende: (a) un compuesto que tiene la fórmula: R1-Z-R2 en la que R1 es H, alquilo C1-4, acetilo, formilo, benzoílo, o trifluoroacetilo; R2 es OH o NH2; y Z es un péptido que tiene la fórmula: His-X2-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-X12-Tyr-Leu-Asp-X16-X17-Ala-Ala-X20-X21-Phe-Val-X24-Trp-Leu-X27-X28-Ala-X30 en la que X2 se selecciona entre Aib y Ser; X12 se selecciona entre Lys, Arg, o Leu; X16 se selecciona entre Arg y X; X17 se selecciona entre Arg y X; X20 se selecciona entre Arg, His y X; X21 se selecciona entre Asp y Glu; X24 se selecciona entre Ala y X; X27 se selecciona entre Leu y X; X28 se selecciona entre Arg y X; X30 es X o está ausente; en la que al menos uno de X16, X17, X20, X24, X27, X28 y X30 es X; y en la que cada resto X se selecciona independientemente entre el grupo que consiste en Glu, Lys, Ser, Cys, Dbu, Dpr y Orn; en la que la cadena lateral de al menos un resto X está conjugada con un sustituyente lipófilo que tiene la fórmula: (i) Z1, en la que Z1 es un resto lipófilo conjugado directamente con la cadena lateral de X; o (ii) Z1Z2, en la que Z1 es un resto lipófilo, Z2 es un espaciador, y Z1 está conjugado con la cadena lateral de X a través de Z2; y (b) un análogo de insulina.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161434698P | 2011-01-20 | 2011-01-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR085086A1 true AR085086A1 (es) | 2013-09-11 |
Family
ID=45607302
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP120100195A AR085086A1 (es) | 2011-01-20 | 2012-01-20 | Uso de analogos de glucagon acilados |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US20140011733A1 (es) |
| EP (1) | EP2665487A1 (es) |
| JP (1) | JP2014504597A (es) |
| KR (1) | KR20140043709A (es) |
| CN (1) | CN103491975B (es) |
| AR (1) | AR085086A1 (es) |
| AU (1) | AU2012208349A1 (es) |
| BR (1) | BR112013018269A2 (es) |
| CA (1) | CA2824397A1 (es) |
| CL (1) | CL2013002085A1 (es) |
| CO (1) | CO6761400A2 (es) |
| EA (1) | EA201390796A1 (es) |
| MA (1) | MA34913B1 (es) |
| MX (1) | MX2013008005A (es) |
| PE (1) | PE20140969A1 (es) |
| SG (1) | SG192038A1 (es) |
| TN (1) | TN2013000251A1 (es) |
| TW (1) | TW201247702A (es) |
| UY (1) | UY33872A (es) |
| WO (1) | WO2012098462A1 (es) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2008365556A1 (en) | 2008-12-15 | 2011-07-21 | Zealand Pharma A/S | Glucagon analogues |
| EP2370461B1 (en) | 2008-12-15 | 2013-10-02 | Zealand Pharma A/S | Glucagon analogues |
| EA020537B1 (ru) | 2008-12-15 | 2014-11-28 | Зилэнд Фарма А/С | Аналоги глюкагона |
| US8680049B2 (en) | 2008-12-15 | 2014-03-25 | Zealand Pharma A/S | Glucagon analogues |
| AU2010272944B2 (en) | 2009-07-13 | 2015-11-19 | Zealand Pharma A/S | Acylated glucagon analogues |
| AR081975A1 (es) | 2010-06-23 | 2012-10-31 | Zealand Pharma As | Analogos de glucagon |
| EA201291234A1 (ru) | 2010-06-24 | 2013-07-30 | Зилэнд Фарма А/С | Аналоги глюкагона |
| EP2758426B1 (en) | 2011-09-23 | 2019-08-07 | Novo Nordisk A/S | Novel glucagon analogues |
| CN104470948B (zh) | 2012-05-03 | 2018-06-15 | 西兰制药公司 | Gip-glp-1双激动剂化合物及方法 |
| CA2878991C (en) | 2012-07-23 | 2021-12-07 | Zealand Pharma A/S | Glucagon analogues |
| TWI608013B (zh) * | 2012-09-17 | 2017-12-11 | 西蘭製藥公司 | 升糖素類似物 |
| KR20150131213A (ko) * | 2013-03-14 | 2015-11-24 | 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 | 인슐린-인크레틴 접합체들 |
| AU2014255608B2 (en) | 2013-04-18 | 2018-01-25 | Novo Nordisk A/S | Stable, protracted GLP-1/glucagon receptor co-agonists for medical use |
| AR098065A1 (es) | 2013-10-17 | 2016-04-27 | Zealand Pharma As | Análogos de glucagón acilados |
| US9988429B2 (en) * | 2013-10-17 | 2018-06-05 | Zealand Pharma A/S | Glucagon analogues |
| WO2015067715A2 (en) | 2013-11-06 | 2015-05-14 | Zealand Pharma A/S | Gip-glp-1 dual agonist compounds and methods |
| EA035688B1 (ru) | 2013-11-06 | 2020-07-27 | Зилэнд Фарма А/С | Соединения, которые представляют собой тройные агонисты глюкагона, glp-1 и gip |
| AR098616A1 (es) | 2013-12-18 | 2016-06-01 | Lilly Co Eli | Péptido para el tratamiento de hipoglicemia severa |
| MA39301A1 (fr) | 2014-01-20 | 2018-01-31 | Hanmi Pharmaceutical Co Ltd | Insuline à action prolongée et utilisation associée |
| AR100639A1 (es) | 2014-05-29 | 2016-10-19 | Hanmi Pharm Ind Co Ltd | Composición para tratar diabetes que comprende conjugados de análogos de insulina de acción prolongada y conjugados de péptidos insulinotrópicos de acción prolongada |
| AR100695A1 (es) | 2014-05-30 | 2016-10-26 | Hanmi Pharm Ind Co Ltd | Composición para el tratamiento de diabetes mellitus que comprende insulina y un agonista dual glp-1 / glucagón |
| EP3151852A1 (en) | 2014-06-04 | 2017-04-12 | Novo Nordisk A/S | Glp-1/glucagon receptor co-agonists for medical use |
| US10232020B2 (en) | 2014-09-24 | 2019-03-19 | Indiana University Research And Technology Corporation | Incretin-insulin conjugates |
| EP3985016A1 (en) | 2014-10-29 | 2022-04-20 | Zealand Pharma A/S | Gip agonist compounds and methods |
| KR20170137198A (ko) | 2015-04-16 | 2017-12-12 | 질랜드 파마 에이/에스 | 아실화된 글루카곤 유사체 |
| UY36870A (es) | 2015-08-28 | 2017-03-31 | Hanmi Pharm Ind Co Ltd | Análogos de insulina novedosos |
| TWI622596B (zh) | 2015-10-26 | 2018-05-01 | 美國禮來大藥廠 | 升糖素受體促效劑 |
| BR102015031283A2 (pt) * | 2015-12-14 | 2018-09-18 | Univ Rio De Janeiro | Bioconjugado de amilina humana ou de análogos de amilinanão agregantes, composição, métodos para a preparação deuma composição, para o tratamento de uma doença oucondição e para estabilizar um composto amilino-mimético, e,medicamento |
| WO2017160669A1 (en) * | 2016-03-18 | 2017-09-21 | Merck Sharp & Dohme Corp. | Insulin-incretin conjugates |
| WO2017189342A1 (en) * | 2016-04-26 | 2017-11-02 | Merck Sharp & Dohme Corp. | Insulin dimer-incretin conjugates |
| JP7158378B2 (ja) | 2016-09-23 | 2022-10-21 | ハンミ ファーマシューティカル カンパニー リミテッド | インスリン受容体との結合力が減少された、インスリンアナログ及びその用途 |
| US11752216B2 (en) | 2017-03-23 | 2023-09-12 | Hanmi Pharm. Co., Ltd. | Insulin analog complex with reduced affinity for insulin receptor and use thereof |
| JP2022514835A (ja) * | 2018-12-21 | 2022-02-16 | ハンミ ファーマシューティカル カンパニー リミテッド | インスリン及びグルカゴンを含む薬学組成物 |
| WO2021252844A1 (en) * | 2020-06-11 | 2021-12-16 | Abvance Therapeutics Inc. | Systems, devices, compositions, and methods for treating diabetes |
| WO2023088140A1 (zh) * | 2021-11-19 | 2023-05-25 | 南京明德新药研发有限公司 | 订合肽及其应用 |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3837825A1 (de) | 1988-11-08 | 1990-05-10 | Hoechst Ag | Neue insulinderivate, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung |
| AU682061B2 (en) | 1993-09-17 | 1997-09-18 | Novo Nordisk A/S | Acylated insulin |
| US6011007A (en) | 1993-09-17 | 2000-01-04 | Novo Nordisk A/S | Acylated insulin |
| US6869930B1 (en) | 1993-09-17 | 2005-03-22 | Novo Nordisk A/S | Acylated insulin |
| US5461031A (en) | 1994-06-16 | 1995-10-24 | Eli Lilly And Company | Monomeric insulin analog formulations |
| US5866538A (en) | 1996-06-20 | 1999-02-02 | Novo Nordisk A/S | Insulin preparations containing NaCl |
| PT944648E (pt) | 1996-08-30 | 2007-06-26 | Novo Nordisk As | Derivados do glp-1. |
| DE69732640T2 (de) | 1996-09-09 | 2006-01-12 | Zealand Pharma A/S | Festphasen-peptidsynthese |
| DE19726167B4 (de) | 1997-06-20 | 2008-01-24 | Sanofi-Aventis Deutschland Gmbh | Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung |
| US6451987B1 (en) | 1999-03-15 | 2002-09-17 | Novo Nordisk A/S | Ion exchange chromatography of proteins and peptides |
| BR0009040A (pt) | 1999-03-17 | 2001-12-18 | Novo Nordisk As | Método para acilar um grupo amino de um peptìdeoou de uma proteìna, e, composto |
| WO2003053460A1 (en) | 2001-12-19 | 2003-07-03 | Eli Lilly And Company | Crystalline compositions for controlling blood glucose |
| WO2003053339A2 (en) | 2001-12-20 | 2003-07-03 | Eli Lilly And Company | Insulin molecule having protracted time action |
| DE10227232A1 (de) | 2002-06-18 | 2004-01-15 | Aventis Pharma Deutschland Gmbh | Saure Insulinzubereitungen mit verbesserter Stabilität |
| KR20050121748A (ko) | 2003-04-29 | 2005-12-27 | 일라이 릴리 앤드 캄파니 | 연장된 시간 작용을 갖는 인슐린 유사체 |
| KR101349808B1 (ko) | 2005-06-13 | 2014-02-13 | 임페리얼 이노베이션스 리미티드 | 섭취행동에 관한 신규 화합물들 및 이들의 효능 |
| US8343914B2 (en) | 2006-01-06 | 2013-01-01 | Case Western Reserve University | Fibrillation resistant proteins |
| CN101389648B (zh) | 2006-02-22 | 2013-07-17 | 默沙东公司 | 肽胃泌酸调节素衍生物 |
| ES2554773T3 (es) | 2006-10-04 | 2015-12-23 | Case Western Reserve University | Insulina y análogos de la insulina resistentes a la fibrilación |
| TWI428346B (zh) | 2006-12-13 | 2014-03-01 | Imp Innovations Ltd | 新穎化合物及其等對進食行為影響 |
| EP2111414B1 (en) | 2007-02-15 | 2014-07-02 | Indiana University Research and Technology Corporation | Glucagon/glp-1 receptor co-agonists |
| ATE520714T1 (de) | 2007-06-15 | 2011-09-15 | Zealand Pharma As | Glucagonanaloga |
| JP5547083B2 (ja) | 2007-11-20 | 2014-07-09 | アンブルックス，インコーポレイテッド | 修飾されたインスリンポリペプチドおよびそれらの使用 |
| DE102008003566A1 (de) | 2008-01-09 | 2009-07-16 | Sanofi-Aventis Deutschland Gmbh | Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil |
| AU2009203810B2 (en) | 2008-01-09 | 2013-07-25 | Sanofi-Aventis Deutschland Gmbh | Novel insulin derivatives having an extremely delayed time-action profile |
| DE102008003568A1 (de) | 2008-01-09 | 2009-07-16 | Sanofi-Aventis Deutschland Gmbh | Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil |
| DK2229407T3 (en) | 2008-01-09 | 2017-02-27 | Sanofi Aventis Deutschland | NEW INSULIN DERIVATIVES WITH EXTREMELY DELAYED TIME / EFFECTS PROFILE |
| WO2009129250A2 (en) | 2008-04-14 | 2009-10-22 | Case Western Reserve University | Meal-time insulin analogues of enhanced stability |
| KR20110021758A (ko) | 2008-04-22 | 2011-03-04 | 케이스 웨스턴 리저브 유니버시티 | 이형체-특이적 인슐린 유사체 |
| TWI451876B (zh) | 2008-06-13 | 2014-09-11 | Lilly Co Eli | 聚乙二醇化之離脯胰島素化合物 |
| KR20110039230A (ko) * | 2008-06-17 | 2011-04-15 | 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 | 생리학적 ｐＨ 완충액에서 강화된 용해도 및 안정성을 나타내는 글루카곤 유사체 |
| EA019203B9 (ru) | 2008-06-17 | 2014-03-31 | Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн | Коагонисты глюкагонового рецептора/glp-1-рецептора |
| PL219335B1 (pl) | 2008-07-04 | 2015-04-30 | Inst Biotechnologii I Antybiotyków | Pochodna insuliny lub jej farmaceutycznie dopuszczalna sól, jej zastosowanie oraz zawierająca ją kompozycja farmaceutyczna |
| KR20110061552A (ko) | 2008-07-31 | 2011-06-09 | 케이스 웨스턴 리저브 유니버시티 | 할로겐 안정화된 인슐린 |
| EP2370461B1 (en) * | 2008-12-15 | 2013-10-02 | Zealand Pharma A/S | Glucagon analogues |
| EA020537B1 (ru) * | 2008-12-15 | 2014-11-28 | Зилэнд Фарма А/С | Аналоги глюкагона |
| US8680049B2 (en) * | 2008-12-15 | 2014-03-25 | Zealand Pharma A/S | Glucagon analogues |
| AU2008365556A1 (en) * | 2008-12-15 | 2011-07-21 | Zealand Pharma A/S | Glucagon analogues |
| CA2747490C (en) | 2008-12-19 | 2017-02-14 | Indiana University Research And Technology Corporation | Insulin analogs |
| CA2744558A1 (en) | 2008-12-19 | 2010-07-15 | Indiana University Research And Technology Corporation | Amide-based insulin prodrugs |
| CN101519446A (zh) | 2009-03-31 | 2009-09-02 | 上海一就生物医药有限公司 | 一种重组人胰岛素及其类似物的制备方法 |
| AU2010272944B2 (en) * | 2009-07-13 | 2015-11-19 | Zealand Pharma A/S | Acylated glucagon analogues |
| JP5969461B2 (ja) * | 2010-04-27 | 2016-08-17 | ジーランド ファーマ アクティーゼルスカブ | Ｇｌｐ−１受容体作動薬とガストリンとのペプチド複合体及びその使用 |
| AR081975A1 (es) * | 2010-06-23 | 2012-10-31 | Zealand Pharma As | Analogos de glucagon |
-
2012
- 2012-01-20 BR BR112013018269A patent/BR112013018269A2/pt not_active IP Right Cessation
- 2012-01-20 EA EA201390796A patent/EA201390796A1/ru unknown
- 2012-01-20 US US13/980,087 patent/US20140011733A1/en not_active Abandoned
- 2012-01-20 AR ARP120100195A patent/AR085086A1/es unknown
- 2012-01-20 KR KR1020137018388A patent/KR20140043709A/ko not_active Application Discontinuation
- 2012-01-20 CA CA2824397A patent/CA2824397A1/en not_active Abandoned
- 2012-01-20 JP JP2013549906A patent/JP2014504597A/ja active Pending
- 2012-01-20 WO PCT/IB2012/000134 patent/WO2012098462A1/en active Application Filing
- 2012-01-20 SG SG2013055090A patent/SG192038A1/en unknown
- 2012-01-20 EP EP12704117.6A patent/EP2665487A1/en not_active Withdrawn
- 2012-01-20 MA MA36191A patent/MA34913B1/fr unknown
- 2012-01-20 AU AU2012208349A patent/AU2012208349A1/en not_active Abandoned
- 2012-01-20 PE PE2013001533A patent/PE20140969A1/es not_active Application Discontinuation
- 2012-01-20 TW TW101102724A patent/TW201247702A/zh unknown
- 2012-01-20 CN CN201280005920.1A patent/CN103491975B/zh not_active Expired - Fee Related
- 2012-01-20 MX MX2013008005A patent/MX2013008005A/es not_active Application Discontinuation
- 2012-01-20 UY UY0001033872A patent/UY33872A/es not_active Application Discontinuation
-
2013
- 2013-06-11 TN TNP2013000251A patent/TN2013000251A1/fr unknown
- 2013-07-11 CO CO13165262A patent/CO6761400A2/es unknown
- 2013-07-19 CL CL2013002085A patent/CL2013002085A1/es unknown
-
2015
- 2015-09-17 US US14/857,067 patent/US20160000883A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| TW201247702A (en) | 2012-12-01 |
| CL2013002085A1 (es) | 2013-12-06 |
| CN103491975A (zh) | 2014-01-01 |
| CO6761400A2 (es) | 2013-09-30 |
| EA201390796A1 (ru) | 2014-07-30 |
| TN2013000251A1 (en) | 2014-11-10 |
| CA2824397A1 (en) | 2012-07-26 |
| US20140011733A1 (en) | 2014-01-09 |
| PE20140969A1 (es) | 2014-07-24 |
| MX2013008005A (es) | 2013-08-21 |
| CN103491975B (zh) | 2016-05-11 |
| MA34913B1 (fr) | 2014-02-01 |
| SG192038A1 (en) | 2013-08-30 |
| KR20140043709A (ko) | 2014-04-10 |
| BR112013018269A2 (pt) | 2017-06-06 |
| EP2665487A1 (en) | 2013-11-27 |
| AU2012208349A1 (en) | 2013-07-18 |
| JP2014504597A (ja) | 2014-02-24 |
| US20160000883A1 (en) | 2016-01-07 |
| UY33872A (es) | 2012-08-31 |
| WO2012098462A1 (en) | 2012-07-26 |
| NZ612719A (en) | 2015-05-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR085086A1 (es) | Uso de analogos de glucagon acilados | |
| NZ597981A (en) | Acylated glucagon analogues | |
| AR081975A1 (es) | Analogos de glucagon | |
| AR105816A2 (es) | Derivados de exendina-4 funcionalizada | |
| TN2012000010A1 (en) | Long acting insulin composition | |
| UY31596A1 (es) | Nuevos derivados de insulina con perfil tiempo/accion extremadamente retardado | |
| SG178984A1 (en) | Novel pyrimidine and triazine hepcidine antagonists | |
| CL2008003153A1 (es) | Compuestos espiro condensados, agonistas de gpr40: composicion farmaceutica que comprende a uno de los compuestos; y el uso de los compuestos en la preparacion de medicamentos para el tratamiento de la diabetes, hiperglicemia, alteracion de tolerancia a la glucosa en ayuna, entre otras. | |
| NI201100213A (es) | Péptidos específicos para receptores de melanocortina | |
| CO6410287A2 (es) | Composición farmacéutica, forma farmacéutica, procedimiento para su preparación, métodos de tratamiento y usos de la misma | |
| RU2012128547A (ru) | Дважды ацилированные производные glp-1 | |
| CU20110129A7 (es) | Piridiloxi-indoles inhibidores del vegf-r2 y uso de los mismos para el tratamiento de enfermedades | |
| AR083787A1 (es) | Composicion farmaceutica que comprende un inhibidor del transportador 2 de sodio-glucosa (sglt2) y una insulina, procedimientos de tratamiento y usos de la misma | |
| EA201171333A1 (ru) | Кристаллические сольваты и комплексы производных (1s)-1,5-ангидро-1-с-(3-((фенил)метил)фенил)-d-глюцитола с аминокислотами в качестве ингибиторов sglt2 для лечения диабета | |
| MX2011012337A (es) | Nuevos derivados de pirimidina y su uso en el tratamiento de cancer y de otras enfermedades. | |
| PE20091655A1 (es) | Farmaco para el cancer de higado | |
| BR112012018116A2 (pt) | "hormônios do crescimento com eficácia in vivo prolongada" | |
| MY155658A (en) | A-isopropylphenyl glucitol compounds as sglti inhibitors | |
| EA201390010A1 (ru) | Замещенные триазолопиридины | |
| MX2010010505A (es) | Imidazoquinolinas y derivados de pirimidina como moduladores potentes de los procesos angiogenicos impulsados por el factor de crecimiento endotelial vascular (vegf). | |
| WO2010080756A3 (en) | Harmine derivatives for reducing body weight | |
| EA201391525A1 (ru) | Гликозидные производные и их применение для лечения диабета | |
| GT200900126A (es) | Novedosos anticuerpos antiproliferacion | |
| PH12015501931A1 (en) | Treatment of diabetes mellitus by long-acting formulations of insulins | |
| NZ598096A (en) | Pharmaceutical compositions for the treatment of cancer and other diseases or disorders |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |